NL300920I2 - inotuzumab ozogamicine - Google Patents

inotuzumab ozogamicine Download PDF

Info

Publication number
NL300920I2
NL300920I2 NL300920C NL300920C NL300920I2 NL 300920 I2 NL300920 I2 NL 300920I2 NL 300920 C NL300920 C NL 300920C NL 300920 C NL300920 C NL 300920C NL 300920 I2 NL300920 I2 NL 300920I2
Authority
NL
Netherlands
Prior art keywords
disclosed
antibody
cdr
antibody molecules
inotuzumab ozogamicin
Prior art date
Application number
NL300920C
Other languages
English (en)
Other versions
NL300920I1 (nl
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300920(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of NL300920I1 publication Critical patent/NL300920I1/nl
Publication of NL300920I2 publication Critical patent/NL300920I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NL300920C 2002-05-02 2017-12-21 inotuzumab ozogamicine NL300920I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products
PCT/GB2003/001934 WO2003093320A2 (en) 2002-05-02 2003-05-02 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses

Publications (2)

Publication Number Publication Date
NL300920I1 NL300920I1 (nl) 2018-01-03
NL300920I2 true NL300920I2 (nl) 2021-04-15

Family

ID=9935990

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300920C NL300920I2 (nl) 2002-05-02 2017-12-21 inotuzumab ozogamicine

Country Status (35)

Country Link
US (8) US7355011B2 (nl)
EP (1) EP1504035B9 (nl)
JP (3) JP4486494B2 (nl)
KR (3) KR101156796B1 (nl)
CN (3) CN100384878C (nl)
AT (1) ATE462729T3 (nl)
AU (1) AU2003223007C1 (nl)
BE (1) BE2017C068I2 (nl)
CA (1) CA2484420C (nl)
CO (1) CO5631451A2 (nl)
CY (3) CY1110134T1 (nl)
DE (1) DE60331910D1 (nl)
DK (1) DK1504035T6 (nl)
EC (1) ECSP045470A (nl)
ES (1) ES2341708T7 (nl)
FR (1) FR17C1062I2 (nl)
GB (1) GB0210121D0 (nl)
HK (2) HK1071762A1 (nl)
HU (2) HUS1700056I1 (nl)
IL (1) IL164923A (nl)
LT (2) LTPA2017043I1 (nl)
LU (2) LUC00057I2 (nl)
MX (1) MXPA04010787A (nl)
NL (1) NL300920I2 (nl)
NO (1) NO336201B1 (nl)
NZ (1) NZ536757A (nl)
PL (1) PL218433B1 (nl)
PT (1) PT1504035E (nl)
RU (1) RU2342401C2 (nl)
SG (1) SG161744A1 (nl)
SI (1) SI1504035T1 (nl)
TW (1) TWI324161B (nl)
UA (1) UA92580C2 (nl)
WO (1) WO2003093320A2 (nl)
ZA (1) ZA200408851B (nl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342929T3 (es) * 2001-09-26 2010-07-19 The Government of the United States of America as represented by the Secretary of Health and Human Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22.
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20030202975A1 (en) 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
DK1507556T3 (en) * 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
AR052774A1 (es) * 2004-10-08 2007-04-04 Wyeth Corp Inmunoterapia para trastornos autoinmunes
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2007103470A2 (en) 2006-03-06 2007-09-13 Medimmune, Inc. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2446904B1 (en) 2006-05-30 2015-04-29 Genentech, Inc. Anti-CD22 antibodies, their immunoconjugates and uses thereof
NZ578064A (en) * 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010096394A2 (en) * 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CA2824143C (en) 2011-01-14 2018-12-18 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
KR20150008080A (ko) * 2012-04-26 2015-01-21 바이오아트라, 엘엘씨 항-cd22 항체
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
US9181343B2 (en) 2012-07-19 2015-11-10 Redwood Bioscience Inc. Antibody specific for CD22 and methods of use thereof
CN110229834B (zh) 2012-10-24 2022-11-01 美国卫生和人力服务部 M971嵌合抗原受体
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
AU2014342610A1 (en) 2013-11-04 2016-06-02 Abbvie Stemcentrx Llc Anti-EFNA4 antibody-drug conjugates
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
KR20180135458A (ko) 2016-04-26 2018-12-20 알.피.쉐러 테크놀러지즈 엘엘씨 항체 컨쥬게이트 및 이의 제조 및 이용 방법
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
EA201990998A1 (ru) 2016-10-21 2019-11-29 Фармацевтические составы и способы их получения
WO2019191704A1 (en) * 2018-03-30 2019-10-03 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
JP2023521635A (ja) * 2020-04-02 2023-05-25 ナンチン イアソ バイオセラピューティクス カンパニー，リミティド 全ヒト化抗ヒトｃｄ２２のキメラ抗原受容体及びその応用
CN114106177B (zh) * 2020-08-27 2024-04-09 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
AU2022333837A1 (en) * 2021-08-27 2024-03-14 Peptron, Inc. Novel anti-muc1 antibody and use thereof
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2264239T3 (es) * 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
US5558864A (en) * 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
NZ291621A (en) 1994-08-12 1998-09-24 Myriad Genetics Inc Isolation and detection of human breast cancer and ovarian cancer predisposing gene, brca1
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
CA2270288A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
JP2002501488A (ja) 1997-03-20 2002-01-15 アメリカ合衆国 Ｃｄ２２を保有する細胞および腫瘍へ標的化された、組換え抗体および免疫複合体
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
EP1232392B2 (de) * 1999-10-12 2014-04-02 Oxoid (Ely) Limited Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU6461201A (en) * 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
DK1507556T3 (en) * 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
US8389688B2 (en) * 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Also Published As

Publication number Publication date
NL300920I1 (nl) 2018-01-03
ES2341708T3 (es) 2010-06-25
PL218433B1 (pl) 2014-12-31
KR20110004463A (ko) 2011-01-13
GB0210121D0 (en) 2002-06-12
DE60331910D1 (de) 2010-05-12
SI1504035T1 (sl) 2010-07-30
KR101156796B1 (ko) 2012-06-21
US20170145114A1 (en) 2017-05-25
IL164923A (en) 2012-03-29
CN1662558A (zh) 2005-08-31
EP1504035B8 (en) 2018-02-28
US8895714B2 (en) 2014-11-25
CY2017045I1 (el) 2019-11-27
LTC1504035I2 (lt) 2022-04-11
ZA200408851B (en) 2006-01-25
NO20044742L (no) 2004-12-22
LUC00058I1 (nl) 2017-12-27
MXPA04010787A (es) 2005-03-07
SG161744A1 (en) 2010-06-29
EP1504035B1 (en) 2010-03-31
JP5377173B2 (ja) 2013-12-25
WO2003093320A2 (en) 2003-11-13
CY2017045I2 (el) 2019-11-27
US7355011B2 (en) 2008-04-08
ATE462729T3 (de) 2010-04-15
LTPA2017043I1 (lt) 2018-01-10
JP2006506955A (ja) 2006-03-02
US20100021995A1 (en) 2010-01-28
NZ536757A (en) 2006-06-30
JP5920934B2 (ja) 2016-05-18
TW200307690A (en) 2003-12-16
IL164923A0 (en) 2005-12-18
JP2013230158A (ja) 2013-11-14
HUS1700056I1 (hu) 2018-07-30
US20070059307A1 (en) 2007-03-15
ES2341708T7 (es) 2018-04-11
LUC00057I2 (nl) 2018-02-26
AU2003223007C1 (en) 2019-08-08
FR17C1062I2 (fr) 2020-05-29
JP4486494B2 (ja) 2010-06-23
CA2484420C (en) 2014-09-16
HK1071762A1 (en) 2005-07-29
KR101386376B1 (ko) 2014-04-16
LUC00057I1 (nl) 2017-12-27
US20120302739A1 (en) 2012-11-29
DK1504035T3 (da) 2010-06-07
EP1504035B3 (en) 2017-12-20
CN103172742B (zh) 2016-05-11
DK1504035T6 (en) 2018-03-12
CY1110134T1 (el) 2015-01-14
US20160326247A1 (en) 2016-11-10
LTPA2017044I1 (lt) 2018-01-10
JP2010022372A (ja) 2010-02-04
PT1504035E (pt) 2010-06-07
US7919606B2 (en) 2011-04-05
AU2003223007A1 (en) 2003-11-17
US20110165659A1 (en) 2011-07-07
EP1504035A2 (en) 2005-02-09
UA92580C2 (ru) 2010-11-25
TWI324161B (en) 2010-05-01
CO5631451A2 (es) 2006-04-28
EP1504035B9 (en) 2018-10-17
CN101134779A (zh) 2008-03-05
CN101134779B (zh) 2013-03-13
ECSP045470A (es) 2005-01-28
PL373277A1 (en) 2005-08-22
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
KR101238970B1 (ko) 2013-03-04
WO2003093320A3 (en) 2004-02-05
RU2004135103A (ru) 2005-10-27
US20030235869A1 (en) 2003-12-25
US20210371547A1 (en) 2021-12-02
CN100384878C (zh) 2008-04-30
HK1186479A1 (zh) 2014-03-14
AU2003223007B2 (en) 2009-07-16
BE2017C068I2 (nl) 2022-08-09
NO336201B1 (no) 2015-06-15
CA2484420A1 (en) 2003-11-13
FR17C1062I1 (nl) 2018-02-16
CN103172742A (zh) 2013-06-26
CY2017046I1 (el) 2018-12-12
KR20050025167A (ko) 2005-03-11
LUC00058I2 (nl) 2018-02-26
CY2017046I2 (el) 2018-12-12
HUS1700055I1 (hu) 2018-07-30
RU2342401C2 (ru) 2008-12-27

Similar Documents

Publication Publication Date Title
NL300920I2 (nl) inotuzumab ozogamicine
ATE482234T1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
AP2092A (en) Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
TW200635946A (en) Binding proteins specific for human matriptase
TH59463B (th) ผลิตภัณฑ์ชีวภาพ